Find Clinical Trial

A phase 1, open label, non-comparative, monocenter study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory B acute lymphoblastic leukaemia – UCART19_PALL

← Back
Study Phase

Phase 1

Therapeutic Area


Active substance/
Medical device

S068587, UCART19

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS068587
Protocol CodeCL1-68587-001
EudraCT Code2015-004293-15
NCT CodeNCT02808442

Documents and links

Results are not yet available.

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.